A5065857402- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- interferon and immune responses
- PARP inhibition in cancer therapy
- Biochemical and Molecular Research
- Melanoma and MAPK Pathways
- Nanoparticle-Based Drug Delivery
- Cutaneous Melanoma Detection and Management
- DNA Repair Mechanisms
- Sirtuins and Resveratrol in Medicine
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Protein Degradation and Inhibitors
- Ferroptosis and cancer prognosis
- Autophagy in Disease and Therapy
- Endoplasmic Reticulum Stress and Disease
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Diet and metabolism studies
- Computational Drug Discovery Methods
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
Yale University
2021-2024
University of New Haven
2022-2024
Whitehead Institute for Biomedical Research
2020
Birla Institute of Technology and Science - Hyderabad Campus
2018
Birla Institute of Technology and Science, Pilani
2018
<p>Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.</p>
<p>Differential expression of SKO vs YRG cells, by RNAseq.</p>
<p>Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3:</p>
<p>List of primers used to perform RT-qPCR on YUDOSO cells related Figure S6.</p>
<p>Figure S5: Evaluation of SETDB1 knockdown in human melanoma cells, related to Figure 4:</p>
<p>Figure S1: Experimental validation of SETDB1 knockout and flow gating schemes, related to Figure 4</p>
<p>Figure S2: CRISPR screen guide distributions, related to Figure 1</p>
<p>Figure S3: Validation and characterization of Setdb1<sup>-/-</sup> cell lines, tumors, microenvironments, related to Figure 2.</p>
<div>Abstract<p>Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators immunity we performed a whole-genome CRISPR screen melanoma and identified <i>Setdb1</i> as well all components human silencing hub complex. We found that loss leads increased immunogenicity complete tumor clearance CD8<sup>+</sup> T cell–dependent manner. Mechanistically, causes...
<p>Figure S6: Characterization of possible SKO tumor antigens, related to Figure 4.</p>
<p>Summary of exonic mutations in YRG cells compared with YMG and WT C57BL6/J cells.</p>
<p>Ranked CRISPR screen dropout hits, related to Figure 1. Analysis was performed using MaGeCK.</p>
Solid lipid nanoparticles (SLNs) represent an affordable, easily scalable, stable and biocompatible drug delivery system with a high to ratio which also improves solubility of poorly soluble drugs.SLNs were developed by using glyceryl monostearate as the single in presence surfactant Poloxamer 188 evaluated efficiency SLNs load therapeutic cargo, curcumin (CUR).The nano-formulation was optimized Quality Design approach understand effect various process parameters on quality attributes,...
Abstract The treatment of primary central nervous system tumors is challenging due to the blood–brain barrier and complex mutational profiles, which associated with low survival rates. However, recent studies have identified common mutations in gliomas [isocitrate dehydrogenase (IDH)-wild-type mutant, WHO grades II–IV; grade IV referred as glioblastomas (GBM)]. These drive epigenetic changes, leading promoter methylation at nicotinic acid phosphoribosyl transferase (NAPRT) gene locus,...
Abstract Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators immunity we performed a whole-genome CRISPR screen melanoma and identified Setdb1 as well all components HUSH complex. We found that loss leads increased immunogenicity complete tumor clearance CD8+ T-cell dependent manner. Mechanistically, causes de-repression endogenous retroviruses (ERVs) cells triggers tumor-cell...
Abstract Cancer associated mutations in citric acid cycle enzymes cause overproduction of 2-hydroxyglutarate (2HG), fumarate, or succinate, commonly referred to as oncometabolites. These oncometabolite-producing are prevalent 70% gliomas, &gt;76% hereditary leiomyomatosis and renal cell carcinoma, &gt;25% paraganglioma pheochromocytomas, respectively contribute their progression. cancers harbor vulnerabilities multiple cellular pathways because competitive inhibition alpha...
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is caused by loss of function mutations in fumarate hydratase (FH) results an aggressive subtype with limited treatment options. Loss FH leads to accumulation fumarate, oncometabolite that disrupts multiple cellular processes drives tumor progression. High levels inhibit alpha ketoglutarate-dependent dioxygenases, including the ten-eleven translocation (TET) enzymes, can lead global DNA hypermethylation. Here, we report patterns...
<div>Abstract<p>The treatment of primary central nervous system tumors is challenging due to the blood–brain barrier and complex mutational profiles, which associated with low survival rates. However, recent studies have identified common mutations in gliomas [isocitrate dehydrogenase (IDH)-wild-type mutant, WHO grades II–IV; grade IV referred as glioblastomas (GBM)]. These drive epigenetic changes, leading promoter methylation at nicotinic acid phosphoribosyl transferase...
<p>Efficacy of BNP GMX1778 in PPM1Dtrnc. isogenic model.</p>
<p>Validation of PLA-PEG GMX1778 efficacy in an IDH1-R132H model.</p>
<p>Validation of PLA-PEG GMX1778 efficacy in an IDH1-R132H model.</p>
<div>Abstract<p>The treatment of primary central nervous system tumors is challenging due to the blood–brain barrier and complex mutational profiles, which associated with low survival rates. However, recent studies have identified common mutations in gliomas [isocitrate dehydrogenase (IDH)-wild-type mutant, WHO grades II–IV; grade IV referred as glioblastomas (GBM)]. These drive epigenetic changes, leading promoter methylation at nicotinic acid phosphoribosyl transferase...
<p>Efficacy of BNP GMX1778 in PPM1Dtrnc. isogenic model.</p>